BR100 Decreased By (-0.7%)
BR30 Decreased By (-0.71%)
KSE100 Decreased By (-0.53%)
KSE30 Decreased By (-0.55%)
BECO 5.66 Decreased By ▼ -0.02 (-0.35%)
BML 63.53 Decreased By ▼ -1.31 (-2.02%)
BOP 33.60 No Change ▼ 0.00 (0%)
CNERGY 8.14 Decreased By ▼ -0.10 (-1.21%)
DCL 11.40 Increased By ▲ 0.05 (0.44%)
FCCL 52.18 Decreased By ▼ -0.73 (-1.38%)
FCSC 5.52 No Change ▼ 0.00 (0%)
FFL 17.75 Decreased By ▼ -0.05 (-0.28%)
FNEL 1.30 No Change ▼ 0.00 (0%)
HUMNL 11.20 Decreased By ▼ -0.04 (-0.36%)
KEL 7.88 Decreased By ▼ -0.09 (-1.13%)
KOSM 5.63 Increased By ▲ 0.19 (3.49%)
MLCF 85.75 Decreased By ▼ -0.26 (-0.3%)
NBP 184.00 Decreased By ▼ -1.00 (-0.54%)
PACE 11.68 Decreased By ▼ -0.34 (-2.83%)
PAEL 40.30 Increased By ▲ 0.09 (0.22%)
PIAHCLA 25.87 Increased By ▲ 0.14 (0.54%)
PIBTL 17.05 Decreased By ▼ -0.27 (-1.56%)
PPL 224.70 Decreased By ▼ -0.60 (-0.27%)
PRL 34.60 Increased By ▲ 0.22 (0.64%)
PTC 64.19 Decreased By ▼ -1.27 (-1.94%)
SEARL 90.40 Decreased By ▼ -0.11 (-0.12%)
SSGC 26.56 Decreased By ▼ -0.20 (-0.75%)
TELE 9.08 Increased By ▲ 0.12 (1.34%)
THCCL 67.23 Decreased By ▼ -2.21 (-3.18%)
TPLP 11.40 Increased By ▲ 0.09 (0.8%)
TREET 24.70 Increased By ▲ 0.15 (0.61%)
TRG 71.14 Decreased By ▼ -0.53 (-0.74%)
WAVES 10.91 Decreased By ▼ -0.54 (-4.72%)
WTL 1.27 Decreased By ▼ -0.01 (-0.78%)

A seven billion dollar (5.2 billion euro) lawsuit pitting the Nigerian government against the world's biggest pharmaceutical company Pfizer opened Tuesday with the US giant demanding the court dismiss the charges. The government is seeking the damages following a drug trial which allegedly led to nearly 200 youngsters either dying or suffering deformities.
Nigeria has based its case on claims that Pfizer had no authorisation or parental consent to carry out the mid-1990s drug trial, while Pfizer insists it had full approval. Government lawyer Babatunde Irukera asked Tuesday to be allowed to introduce "additional facts" before the court, a move contested by Pfizer's legal team.

Copyright Agence France-Presse, 2007

Comments

Comments are closed for this article.